Malaria
(Plasmodia)
Material: | Pathogen demonstration: 2 ml EDTA-blood for blood smears and thick drop
Antigen demonstration: 1 ml EDTA-blood for malaria-antigen quick test In the antigen demonstration, plasmodium falciparum (M. tropica), plasmodium vivax or ovale (M. tertiana) or plasmodium malariae (M. quartana) are detected.
Antibody demonstration: 1 ml serum Antibody demonstration is not suitable for the diagnosis of acute malaria and does not allow a statement about immunity. Serology may be useful in case of patients who have received initial treatment.
PCR: 1 ml EDTA-blood (P. falciparum, vivax, malariae and ovale) External services for clarification of unclear findings. |
Methods: |
Ligandenassays → Enzyme Linked Immunosorbent Assay (ELISA) Amplifikationsverfahren → Real-time-PCR Mikroskopie → Hellfeldmikroskopie | Criteria for evaluation | Antibody demonstration: Malaria IgG: < 0,8 – 1,0 ratio
Captured are antibodies against P. falciparum, P. ovale, P. vivax, P. malariae and P. knowlesi. |
Indication | Fever following a stay in endemic areas. | Mandatory reporting | ja In accordance with §7, paragraph 3 IfSG, the laboratory has to inform the Robert-Koch institute of any direct and indirect pathogen detection, where possible with specification of species, without patient name. |
Please note | Malaria tropica (Plasmodium falciparum) is an infectiological emergency! Diagnosis and commencement of therapy should start immediately! In case of clinical suspicion (clinical picture, matching travel history) but negative microscopic result, repeat tests (3x within 24 hours, in regular intervals) are recommended. Currently, the following types are distinguished: M. tropica (Plasmodium falciparum), M. tertiana (Plasmodium vivax, Plasmodium ovale), M. quartana (Plasmodium malariae), Southeast Asian zoonotic malaria (Plasmodium knowlesi);
Southeast Asian zoonotic malaria: Clinical symptoms are similar to those of malaria tropica; Latest recommendations of the WHO or the German society for tropical medicine (DTG) should be observed as to prophylactic measures when travelling to risk areas and current treatment recommendations, travel medical consultation after prior arrangement by telephone. In patients with known or suspected glucose-6-phosphate dehydrogenase deficiency, primaquine may lead to hemolytic episodes.
Further information can be found at: www.rki.de |
External services | ja MVZ Labor PD Dr. Volkmann und Kollegen Karlsruhe |
Accredited | ja |
More Results for the letter M
- Methylmalonic acid (METHYS)
- Methylphenidate (METHE)
- Ritalin
- Metoprolol (METO)
- Microglobulin (α1-) (MICR04(a1))
- Microsporidia (MICR05)
- of about 100 genii of microsporidia only 5 have a pathogenic significance for humans, among them the Encephalitozoon und Enterocytozoon
- Midazolam (MIDA)
- Mirtazapine (MIRTA)
- Modafinil (MODA)
- Molecular fungal diagnostics, multiplex-PCR (PILZM)
- Molybdenum (MOLY)
- Morphine (MORPH)
- Mother milk (MOTH)
- testing of Insecticides, metals
- MRGN (MRGN)
- Multidrug-resistant gram negative pathogens
- MRSA/ORSA (MRSA)
- Methicillin or oxacillin-resistant staphylococcus aureus
- MTHFR polymorphism (MTHFR)
- 5.10-methylenetetrahydrofolate reductase gene, C677T mutation
- Mucopolysaccharidoses (MUCOSC)
- Mucormycosis (MUMYK)
- Mumps (MUMP)
- Paramyxovirus, serotype 1
- Munc-18 autoantibodies (MUNC)
- Muscle specific receptor tyrosine kinase autoantibodies
- MuSK antibodies
- Mycophenolate Mofetil (MYCOPH)
- Active metabolite: mycophenolic acid
- Mycoplasma genitalium (MG)
- Mycoplasma pneumoniae (MYCO)
- Mycosis (MYKOSE)
- Myelin-associated glycoprotein autoantibodies (MAG)
- Myoglobin in serum (MYOG)
- Myoglobin in urine (MYOGU)
- Myositis autoantibodies, basic panel (MYOSI)
- Mi-2a-, Mi-2b-, TIF1g-, MDA5-, NXP2-, SAE1-, Ku (86,72)-, PM100-, PM75-, Jo-1-, SRP-, PL-7-, PL-12-, EJ-, OJ-, Ro52-, HMGCR-, cN-1A-autoantibodies
- Myositis autoantibodies, supplementary panel
- (KS-, Zo-, Ha-autoantibodies)